SABS•globenewswire•
SAB BIO to Participate in Upcoming Investor Conferences
Summary
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February:
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 4, 2026 by globenewswire